% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@INBOOK{CidreAranaz:294421,
author = {D. Surdez and L. Landuzzi and K. Scotlandi and M. C.
Manara},
editor = {F. Cidre-Aranaz and T. G. P. Grünewald},
title = {{E}wing {S}arcoma {PDX} {M}odels},
volume = {2226},
address = {New York, NY},
publisher = {Springer US},
reportid = {DKFZ-2024-02250},
isbn = {978-1-0716-1019-0 (print)},
series = {Methods in Molecular Biology},
pages = {223 - 242},
year = {2021},
comment = {Ewing Sarcoma / Cidre-Aranaz, Florencia (Editor) ; New
York, NY : Springer US, 2021, Chapter 18 ; ISSN:
1064-3745=1940-6029 ; ISBN:
978-1-0716-1019-0=978-1-0716-1020-6 ;
doi:10.1007/978-1-0716-1020-6},
booktitle = {Ewing Sarcoma / Cidre-Aranaz,
Florencia (Editor) ; New York, NY :
Springer US, 2021, Chapter 18 ; ISSN:
1064-3745=1940-6029 ; ISBN:
978-1-0716-1019-0=978-1-0716-1020-6 ;
doi:10.1007/978-1-0716-1020-6},
abstract = {Ewing sarcoma (EWS) is a rare malignant pediatric tumor and
patient derived xenografts (PDXs) could represent a
possibility to increase the number of available models to
study this disease. Compared to cell derived xenografts
(CDX), PDXs are reported to better recapitulate tumor
microenvironment, heterogeneity, genetic and epigenetic
features and are considered reliable models for their better
predictive value when comparing preclinical efficacy and
treatment response in patients. In this chapter, we
extensively describe a method for generating Ewing sarcoma
PDX models, for their validation and molecular
characterization.},
ddc = {570},
typ = {PUB:(DE-HGF)7},
doi = {10.1007/978-1-0716-1020-6_18},
url = {https://inrepo02.dkfz.de/record/294421},
}